PROK ProKidney Corp.

$2.41

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on Nov 18, 2025
Report Time: After the Bell
The Whisper Number
$0.00
Consensus Estimate: $0.00
Revenue Estimate: $59.00K

Latest Earnings Insight

Updated On 11/17/2025

About ProKidney Corp.

ProKidney Corporation. The company is headquartered in Winston-Salem, North Carolina.

Website: https://prokidney.com

Sector
REAL ESTATE & CONSTRUCTION
Industry
BLANK CHECKS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1850270
Address
2850 W. HORIZON RIDGE PARKWAY, SUITE 200, HENDERSON, NV, US
Valuation
Market Cap
$1.81B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
97.15
Performance
EPS
$-0.62
Dividend Yield
—
Profit Margin
0.00%
ROE
-41.20%
Technicals
50D MA
$1.08
200D MA
$1.75
52W High
$4.44
52W Low
$0.46
Fundamentals
Shares Outstanding
130M
Target Price
$4.67
Beta
1.59

PROK EPS Estimates vs Actual

● Estimated
● Actual

PROK News & Sentiment

Nov 10, 2025 • GlobeNewswire NEUTRAL
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
WINSTON-SALEM, N.C., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( "ProKidney" or the "Company" ) , a leading late clinical-stage cell therapy company focused on chronic kidney disease ( CKD ) , today reported financial results for the third quarter ended September 30, ...
Nov 06, 2025 • Benzinga SOMEWHAT-BULLISH
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 - ProKidney ( NASDAQ:PROK )
In patients with advanced chronic kidney disease ( CKD ) and diabetes, treatment with rilparencel resulted in statistically significant and clinically meaningful slowing of CKD progression
Nov 06, 2025 • GlobeNewswire NEUTRAL
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
WINSTON-SALEM, N.C., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( "ProKidney" or the "Company" ) , a leading late clinical-stage cell therapy company focused on CKD, today presented full results from the Phase 2 REGEN-007 trial evaluating rilparencel in patients with ...
Oct 29, 2025 • GlobeNewswire SOMEWHAT-BULLISH
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
WINSTON-SALEM, N.C., Oct. 29, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( "ProKidney" or the "Company" ) , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease ( CKD ) , today announced that senior members of the management team will be ...
Oct 20, 2025 • GlobeNewswire SOMEWHAT-BULLISH
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025
WINSTON-SALEM, N.C., Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. ( Nasdaq: PROK ) ( "ProKidney" or the "Company" ) , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease ( CKD ) , today announced that the Company will present two posters, ...
Aug 27, 2025 • Benzinga SOMEWHAT-BULLISH
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference - ProKidney ( NASDAQ:PROK )
WINSTON-SALEM, N.C., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- ProKidney Corp. PROK ( "ProKidney" or the "Company" ) , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease ( CKD ) , today announced that senior members of the management team will be participating ...
Sentiment Snapshot

Average Sentiment Score:

0.183
50 articles with scored sentiment

Overall Sentiment:

Bullish

PROK Reported Earnings

Aug 12, 2025
Jun 30, 2025 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.13
  • Estimate: $-0.15
  • Whisper: —
  • Surprise %: 13.3%
May 12, 2025
Mar 31, 2025 (Pre market)
0.03 Surprise
  • Reported EPS: $-0.13
  • Estimate: $-0.16
  • Whisper: —
  • Surprise %: 18.8%
Mar 17, 2025
Dec 31, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.16
  • Estimate: $-0.15
  • Whisper: —
  • Surprise %: -6.7%
Nov 12, 2024
Sep 30, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.14
  • Estimate: $-0.15
  • Whisper: —
  • Surprise %: 5.4%
Aug 09, 2024
Jun 30, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.16
  • Estimate: $-0.17
  • Whisper: —
  • Surprise %: 5.9%
May 10, 2024
Mar 31, 2024 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.16
  • Estimate: $-0.18
  • Whisper: —
  • Surprise %: 11.1%
Mar 21, 2024
Dec 31, 2023 (Pre market)
0.08 Surprise
  • Reported EPS: $-0.09
  • Estimate: $-0.17
  • Whisper: —
  • Surprise %: 47.1%
Nov 14, 2023
Sep 30, 2023 (Pre market)
-0.02 Surprise
  • Reported EPS: $-0.18
  • Estimate: $-0.16
  • Whisper: —
  • Surprise %: -12.5%
Aug 10, 2023
Jun 30, 2023 (Post market)
0.25 Surprise
  • Reported EPS: $-0.14
  • Estimate: $-0.39
  • Whisper: —
  • Surprise %: 64.1%

Financials